Connected insulin pens now compatible with FreeStyle LibreLink app

People living with diabetes in the UK who use Abbott’s FreeStyle LibreLink app with FreeStyle Libre glucose sensing technology, can now connect it to Novo Nordisk’s smart connected pens.

This allows people living with diabetes to see how different factors like dose timing and the amount of insulin taken impact their individual glucose patterns.

Healthcare professionals often ask people living with diabetes to keep a record of their insulin dose data, to add context to their glucose readings. When people tap Novo Nordisk’s smart connected pens, NovoPen 6 or NovoPen Echo Plus, against their smartphone their insulin dose data is automatically uploaded to the FreeStyle LibreLink app. It can then be viewed alongside their glucose data in one place. 

Su Down, nurse consultant in diabetes, Somerset Foundation Trust, said: “Individually these two technologies provide valuable information for people managing their diabetes. Linked together, however they can provide an additional insight into the impact of both dosing and timing of injection on glucose levels. Providing people with diabetes and health care professionals with this insightful information offers an additional perspective, much like adding another piece to the puzzle – we see more of the overall picture, on which to base diabetes management decisions.”

After the COVID-19 pandemic, the Primary Care Diabetes Society (PCDS) forecasted diabetes review backlogs of up to a year. Smart connected pens and glucose sensing technology could play a role to support the NHS in clearing this backlog, as data show they may help people with diabetes reduce their risk of hyper or hypo-glycaemic events.

Novo Nordisk believes that digital health solutions can support people with diabetes and their healthcare professionals with reliable information. We are proud to be working alongside a wide range of partners to help bring digital health solutions to as many people as possible. 

Pinder Sahota, general manager, Novo Nordisk UK, said: “People living with diabetes can make up to 180 additional health-related decisions a day compared to people without diabetes – the constant multi-tasking can be emotionally and physically draining. I hope that bringing glucose and insulin data together in one place will make some of these decisions a little easier, giving people living with diabetes in the UK more time and energy back for day-to-day life.”